744 related articles for article (PubMed ID: 26408163)
1. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
Fernández-Ruiz J; Romero J; Ramos JA
Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease.
Han QW; Yuan YH; Chen NH
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109745. PubMed ID: 31442553
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.
Aymerich MS; Aso E; Abellanas MA; Tolon RM; Ramos JA; Ferrer I; Romero J; Fernández-Ruiz J
Biochem Pharmacol; 2018 Nov; 157():67-84. PubMed ID: 30121249
[TBL] [Abstract][Full Text] [Related]
4. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB
Navarro G; Borroto-Escuela D; Angelats E; Etayo Í; Reyes-Resina I; Pulido-Salgado M; Rodríguez-Pérez AI; Canela EI; Saura J; Lanciego JL; Labandeira-García JL; Saura CA; Fuxe K; Franco R
Brain Behav Immun; 2018 Jan; 67():139-151. PubMed ID: 28843453
[TBL] [Abstract][Full Text] [Related]
5. Type-2 cannabinoid receptors in neurodegeneration.
Bisogno T; Oddi S; Piccoli A; Fazio D; Maccarrone M
Pharmacol Res; 2016 Sep; 111():721-730. PubMed ID: 27450295
[TBL] [Abstract][Full Text] [Related]
6. The endocannabinoid system as a target for the treatment of motor dysfunction.
Fernández-Ruiz J
Br J Pharmacol; 2009 Apr; 156(7):1029-40. PubMed ID: 19220290
[TBL] [Abstract][Full Text] [Related]
7. Endocannabinoid System in Neurological Disorders.
Ranieri R; Laezza C; Bifulco M; Marasco D; Malfitano AM
Recent Pat CNS Drug Discov; 2016; 10(2):90-112. PubMed ID: 27364363
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders.
Antonazzo M; Botta M; Bengoetxea H; Ruiz-Ortega JÁ; Morera-Herreras T
Int Rev Neurobiol; 2019; 146():229-257. PubMed ID: 31349929
[TBL] [Abstract][Full Text] [Related]
9. The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases.
Maccarrone M; Battista N; Centonze D
Prog Neurobiol; 2007 Apr; 81(5-6):349-79. PubMed ID: 17276576
[TBL] [Abstract][Full Text] [Related]
10. Differential upregulation of the cannabinoid CB₂ receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease.
Concannon RM; Okine BN; Finn DP; Dowd E
Exp Neurol; 2015 Jul; 269():133-41. PubMed ID: 25895887
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases.
Pérez-Olives C; Rivas-Santisteban R; Lillo J; Navarro G; Franco R
Adv Exp Med Biol; 2021; 1264():81-92. PubMed ID: 33332005
[TBL] [Abstract][Full Text] [Related]
12. Endocannabinoids and Mental Disorders.
Rubino T; Zamberletti E; Parolaro D
Handb Exp Pharmacol; 2015; 231():261-83. PubMed ID: 26408164
[TBL] [Abstract][Full Text] [Related]
13. The endocannabinoid system in Huntington's disease.
Pazos MR; Sagredo O; Fernández-Ruiz J
Curr Pharm Des; 2008; 14(23):2317-25. PubMed ID: 18781982
[TBL] [Abstract][Full Text] [Related]
14. Role of the endocannabinoid system in Alzheimer's disease: new perspectives.
Pazos MR; Núñez E; Benito C; Tolón RM; Romero J
Life Sci; 2004 Sep; 75(16):1907-15. PubMed ID: 15306158
[TBL] [Abstract][Full Text] [Related]
15. Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease.
Bagher AM; Laprairie RB; Kelly MEM; Denovan-Wright EM
Methods Mol Biol; 2018; 1780():549-571. PubMed ID: 29856035
[TBL] [Abstract][Full Text] [Related]
16. The endocannabinoid system in neuropathological states.
Orgado JM; Fernández-Ruiz J; Romero J
Int Rev Psychiatry; 2009 Apr; 21(2):172-80. PubMed ID: 19367511
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P
Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
[TBL] [Abstract][Full Text] [Related]
18. Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's Disease and Less Well-Known Diseases.
Páez JA; Campillo NE
Curr Med Chem; 2019; 26(18):3300-3340. PubMed ID: 29484980
[TBL] [Abstract][Full Text] [Related]
19. The role of cannabinoids and leptin in neurological diseases.
Agar E
Acta Neurol Scand; 2015 Dec; 132(6):371-80. PubMed ID: 25880465
[TBL] [Abstract][Full Text] [Related]
20. Latest advances in cannabinoid receptor agonists.
Thakur GA; Tichkule R; Bajaj S; Makriyannis A
Expert Opin Ther Pat; 2009 Dec; 19(12):1647-73. PubMed ID: 19939187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
